Page 103 - Revol6

Cristina Abelleira Vidal y Rafael Touriño Glez.
5. Rüsh N, Corrigan P W. Motivational interviewing to improbé
insight and treatment adherence in schizophrenia. Psychiatric
Rehabilitation Journal, 2002, 26 (1): 23-32.
6. Cooke M A; Peters E R, Kuipers E, Kumari V. Disease, deficit or
denial? Models of poor insight in psychosis. Acta Psychiatr
Scand, 2005; 112 (1): 4-17.
7. Lysaker, P.H., & Bell, M.D. Work and meaning: Disturbance of
volition and vocational dysfunction in schizophrenia. Psychiatry,
1995; 58, 392-400.
8. Marková I.S., Berrios G.E. Insight and clinical psychiatry revisi-
ted. Comprehensive Psychiatry, 1995; 36, 367-76.
9. Dominguez Panchón A.I., Marková I.S., Berrios G.E.,,Bulbena
Vilarrasa A. Evaluación del insight en las psicosis. En Bulbena
Vilarrasa A., Berrios G.E., Fernández de Larrionoa P. Medición
clínica en Psiquiatría y Psicología. Barcelona: Masson; 2000:
137-51.
10. David A.S. Insight and psychosis. Br J Psychiatry, 161, 599-602.
11. Amador X., Strauss D.H., Yale S.A., Gorman J.L. Awareness of
illness in schizophrenia. Schizophr Bulletin, 1991; 17,113-32.
12. Amador X.F., Kronengold H. Understanding and assessing
insight. In Insight and Psychosis (second edition) . Oxford:
Oxford University Press, 2005; 3-30.
13. Amador X.F., Strauss D.H. The Scale to asess Unawereness of
Mental Disorder (SUMD). 1990, Columbia University and New
York State Psychiatric Institute.
14. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syn-
drome scale (PANSS) for schizophrenia. Schizophr Bulletin,
1987; 13, 261-76.
15. Haynes R.B. Introduction. En: Haynes R.B, Taylor D.W, Sackett
D.L. (Eds.): Compliance health care. Baltimore: John Hopkins
University Press, 1979; 1-7.
16. Osterberg, L y Blaschke, T. Adherence to medication. N Engl J
Med. 2005;353: 487-97.
17. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J. Medication
compliance feedback and monitoring in a clinical trial: predictors
and outcomes. Value Health 2003; 6:566-73.
18. Chen A. Noncompliace in comunitary Psychiatry: a review of cli-
nical interventions. Hosp Com Psychiatry. 1991; 42: 282-7.
19. Julius RJ, Novitsky JR, Dubin WR. Medication adherence: A
review of the literature and implications for clinical practice.
Journal of Psychiatric Practice. 2009: 15:34-44.
20. Perkins DO. Predictors of noncompliance in patients with schi-
zophrenia. J Clin Psychiatry. 2002; 63:1121-8.
21. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV.
Prevalence of and risk factors for medication nonadherence in
patients with schizophrenia: a comprehensive review of recent
literature. J Cin Psychiatry. 2002, 63: 892-909.
22. Weiden P.J, Dixon L, Frances A, et al. Neuroleptic noncom-
pliance in schizophrenia. En: Tammingan, C; Schulz, C. (Eds.).
Advances in neuropsychiartry an psychopharmacology. Vol.I.
Schizophrenia Research. New York: Raven, 1991.
23. Oehl M, Hummer M, Fleischhacker W.W. Compliance with
antipsychotic treatment. Acta Psychiatr Scand, 2000; suppl 102:
83-6.
24. Helgason L. Twenty years follow up of first psychiatric presenta-
tion for schizophrenia: what could have been prevented? Acta
Psychiatr Scand 1990; 81: 141-5.
25. Wyatt R.J. Medicación antipsicótica y evolución a largo plazo de
la esquizofrenia. En: Shriqui Ch. L, Nasrallah H.A, editores.
Aspectos Actuales del Tratamiento de la Esquizofrenia. Madrid:
Edimsa; 1995: 433-62.
26. Fleischhacker WW, Oehl MA, Hummer M. Factors influencing
compliance in schizophrenia patients. J Clin Psychiatry. 2003;64
(Suppl. 16): 10-3.
27. Fenton WS, Blyler CR, Heinssen RK. Determinants of medica-
tion compliance in schizophrenia: Empirical and clinical fin-
dings. Schizophr Bull. 1997; 23:637-51.
28. Franch Valverde J.I, Conde López V.J.M, Blanco Garrote J.A,
Medina Ojeda G. El incumplimiento terapéutico: concepto,
magnitud, factores relacionados, métodos de detección y medidas
de actuación. Propuesta de un programa para el hospital de día
psiquiátrico. Interpsiquis, 2001 (fecha de acceso 18 de febrero de
2004); (2). URL disponible en: http://www.psiquiatria.com/
interpsiquis2001/2547.
108 Evaluación en Rehabilitación Psicosocial
29. Ascher-Svanum et al. Medication Adherence and Long-Term
Functional Outcomes in the Treatment of Schizophrenia in Usual
Care. J Clin Psychiatry 67:3; March 2006: 453-60.
30. Misdrahi D, Llorca PM, Lanchón C, Bayle FJ. Compliance in
schizophrenia: predictive factors, therapeutical considerations
and research implications. Encephale 2002. May-Jun; 28(3):266-
72.
31. Adams J, Scott J. Predicting medication adherence in severe
mental disorders. Acta Psychiatr Scand 2000; 101: 119-24.
32. Olfson M, Marcus SC, Wilk J, et al. Awareness of illness and
noadherence to antipsychotic medication among persons with
schizophrenia. Psychiatr Serv 2006; 57:205-11.
33. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden
PJ. Predicting medication noncompliance after hospital dischar-
ge among patients with schizophrenia. Psychiatr Serv. 2000;
51:216-22.
34. Owen RR, Fischer EP, Booth BM, Cuffel BJ. Medication non-
compliance and substance abuse among patients with schizoph-
renia. Psychiatr Serv. 1996; 47:853-8.
35. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medica-
tion adherence: is there a difference between typical and atypical
agents? Am J Psychiatry. 2002; 159:103-8.
36. Awad A.G, Subjective response to neuroleptics in schizophrenia.
Schizophr Bull 1993; 19: 609-18.
37. Van Putten T, May P.R, Marder S.R. Subjective responses to
thiothixene and chlorpromazine. Psychopharmacol Bull. 1980;
16(3): 36-8.
38. Karow A, Naber D. Subjective well-being and quality of life
under atypical antipsychotic treatment. Psychopharmacology.
2002; 162: 3-10.
39. Voruganti L, Awad A. Is Neuroleptic Dysphoria a Variant of
Drug-Induced Extrapyramidal Side Effects? Can J Psychiatry.
2004. 49 (5): 285-289.
40. Awad A, Voruganti. Neuroleptic dysphoria: revisiting the con-
cept 50 years later. Acta Psychiatr Scand. 2005. 111(suppl. 427):
6-13.
41. Marder SR. Subjective experiences on antipsychotic medications:
synthesis and conclusions. Acta Psychiatr Scand. 2005; 427:43-6
42. Naber D, Karow A, Lambert M. Subjective well-being under
neuroleptic treatment and its relevance for compliance. Acta
Psychiatr Scand. 2005. 111 (Suppl. 427):29-34.
43. Adams C.E, Fenton M.K, Quraishi S, David A.S. Systematic
meta-review of depot antipsychotic drugs for people with schi-
zophrenia. British Journal of Psychiatry 2001. 179: 290-9.
44. Kane J.M. Strategies for improving compliance in treatment of
schizophrenia by using a longacting formulation of an antipsy-
chotic: clinical studies. Journal of Clinical Psychiatry 2003; 64,
Suppl 16: 34-40.
45. Diaz E, Neuse E, Sullivan MC et al. Adherence to conventional
and atypical antipsychotics after hospital discharge. J Clin
Psychiatry 2004;65:354-60.
46. Kane J.M. Review of treatments that can ameliorate nonadhe-
rence in patients with schizophrenia. J Clin Psychiatry 2006; 67,
Suppl 5: 9-14.
47. Frank A.F, Gunderson J.G. The role of the therapeutic alliance in
the treatment of schizophrenia. Relationship to course and otu-
come. Arch Gen Psychiatry, 1990; 47: 228-36.
48. Marder SR, Mebane A, Chien CP, et al. A comparison of patients
who refuse and consent to neuroleptic treatment. Am J
Psychiatry 1983; 140-72.
49. Makaryus AN, Friedman EA. Patients´ understanding of their
treatment plans and diagnosis at discharge. Mayo Clin Proc
2005; 80: 991-4.
50. McEvoy J.P, Freter S, Everett G, Geller G.L, Appelbaum P,
Apperson L.J et al. Insight and the clinical outcome of schizoph-
renic patients. Journal of Nervous an Mental Diseases 1989. 177:
48-51.
51. Hudson TJ, Owen RR, Thrush CR, Han X, Pyne JM, Thapa P,
et al. A pilot study of barriers to medication adherence in schi-
zophrenia. J Clin Psychiatry. 2004; 65:211-6.
52. Bobes J, García C, Bulbena A. Medición de la adherencia en la
esquizofrenia. En: Cañas F, Roca M (coord.): Adherencia terapéu-
tica en la esquizofrenia y otros trastornos psiquiátricos. Madrid:
Ars Medica. 2006: 85-94.